SCHEDULE: Lincoln Alternative Strategies Discloses 5.42% Stake in Bionano Genomics

Lincoln Alternative Strategies LLC has reported a passive beneficial ownership of 5.42% in Bionano Genomics, Inc., holding 525,000 shares of common stock.

Summary

• Lincoln Alternative Strategies LLC has filed a Schedule 13G, indicating passive beneficial ownership in Bionano Genomics, Inc.
• The reporting person beneficially owns 525,000 shares of Bionano Genomics' common stock.
• This ownership represents 5.42% of the issuer's common stock outstanding as of September 17, 2025.
• The total number of Bionano Genomics' common stock issued and outstanding as of September 17, 2025, was 9,680,265 shares.
• Lincoln Alternative Strategies LLC holds sole voting and sole dispositive power over all 525,000 shares.
• The securities were not acquired or held for the purpose of changing or influencing the control of Bionano Genomics, Inc.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a new institutional investor has disclosed a significant passive stake, which can be interpreted as a vote of confidence in the company. However, the filing itself is purely informational and does not contain operational or financial updates from the company.

Positives

• A new institutional investor, Lincoln Alternative Strategies LLC, has disclosed a significant stake, potentially signaling confidence in Bionano Genomics' long-term prospects.
• The passive nature of the investment (Schedule 13G) suggests a belief in the company's current trajectory without immediate intentions to influence management or control.

Negatives

• No specific negative information was disclosed in this Schedule 13G filing.

Risks

• No specific risks related to Bionano Genomics, Inc. were mentioned in this Schedule 13G filing, as it primarily concerns beneficial ownership disclosure.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Bionano Genomics, Inc. or the reporting person regarding the issuer's future performance.

Industry Context

The disclosure of a new significant passive stake by an alternative strategies firm in a genomics company like Bionano Genomics could be viewed as a positive signal within the biotechnology sector, indicating investor interest in companies focused on genomic analysis and diagnostics.

Stakeholder Impact

• Shareholders: The disclosure of a new institutional investor holding over 5% could be seen as a positive indicator, potentially increasing investor confidence and liquidity for Bionano Genomics' stock.
• Company Management: While the investment is passive, it signifies external validation of the company's value proposition, which could be beneficial for strategic planning and market perception.

Key Dates

Recommendation

The filing indicates a new institutional investor has taken a significant passive stake, which is generally a positive signal. However, a Schedule 13G does not provide new operational or financial data to warrant a 'buy' or 'strong buy' recommendation. It confirms institutional interest, suggesting a 'hold' is appropriate for existing investors, while new investors might consider further due diligence based on this positive indicator.

Keywords

Bionano Genomics, BNGO, Lincoln Alternative Strategies, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Beneficial Ownership, Biotechnology, Genomics